JP2024528877A5 - - Google Patents
Info
- Publication number
- JP2024528877A5 JP2024528877A5 JP2024504840A JP2024504840A JP2024528877A5 JP 2024528877 A5 JP2024528877 A5 JP 2024528877A5 JP 2024504840 A JP2024504840 A JP 2024504840A JP 2024504840 A JP2024504840 A JP 2024504840A JP 2024528877 A5 JP2024528877 A5 JP 2024528877A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- cells
- antibody
- klrg1
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163225828P | 2021-07-26 | 2021-07-26 | |
| US63/225,828 | 2021-07-26 | ||
| US202263308222P | 2022-02-09 | 2022-02-09 | |
| US63/308,222 | 2022-02-09 | ||
| PCT/US2022/038310 WO2023009498A1 (en) | 2021-07-26 | 2022-07-26 | Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024528877A JP2024528877A (ja) | 2024-08-01 |
| JP2024528877A5 true JP2024528877A5 (enExample) | 2025-08-04 |
Family
ID=85087207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024504840A Pending JP2024528877A (ja) | 2021-07-26 | 2022-07-26 | キラー細胞レクチン様受容体サブファミリーｇメンバー１（ｋｌｒｇ１）枯渇性抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250101112A1 (enExample) |
| EP (1) | EP4377346A1 (enExample) |
| JP (1) | JP2024528877A (enExample) |
| AU (1) | AU2022320627A1 (enExample) |
| CA (1) | CA3227742A1 (enExample) |
| MX (1) | MX2024001277A (enExample) |
| WO (1) | WO2023009498A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025147544A1 (en) | 2024-01-02 | 2025-07-10 | Abcuro, Inc. | Methods of treating inclusion body myositis (ibm) |
| WO2026072990A1 (en) | 2024-09-27 | 2026-04-02 | Abcuro, Inc. | Methods of treating t-cell large granular lymphocytic leukemia |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| DE3380726D1 (en) | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
| DK3622815T3 (da) | 2009-07-08 | 2023-06-26 | Kymab Ltd | Gnavermodeller og terapeutiske molekyler |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| AU2017326003A1 (en) | 2016-09-16 | 2019-04-11 | Children's Medical Center Corporation | KLRG1 depletion therapy |
| WO2019169229A1 (en) * | 2018-03-01 | 2019-09-06 | Nextcure, Inc. | Klrg1 binding compositions and methods of use thereof |
| AU2020272939A1 (en) | 2019-04-09 | 2021-11-11 | Abcuro, Inc. | Killer cell lectin-like receptor subfamily G member 1 (KLRG1) depleting antibodies |
-
2022
- 2022-07-26 WO PCT/US2022/038310 patent/WO2023009498A1/en not_active Ceased
- 2022-07-26 CA CA3227742A patent/CA3227742A1/en active Pending
- 2022-07-26 AU AU2022320627A patent/AU2022320627A1/en active Pending
- 2022-07-26 MX MX2024001277A patent/MX2024001277A/es unknown
- 2022-07-26 JP JP2024504840A patent/JP2024528877A/ja active Pending
- 2022-07-26 EP EP22755009.2A patent/EP4377346A1/en active Pending
- 2022-07-26 US US18/291,013 patent/US20250101112A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2563830C2 (ru) | Лечение остеоартрита и боли | |
| CN106554417B (zh) | 抗ox40抗体和使用其的方法 | |
| JP2023123627A5 (enExample) | ||
| JP2022191301A5 (enExample) | ||
| AU784971B2 (en) | Treatment of patients having non-Hodgkins lymphoma with bone marrow involvement with anti-CD20 antibodies | |
| JP2022510964A5 (enExample) | ||
| JP2022528721A5 (enExample) | ||
| JP2021527431A5 (enExample) | ||
| JP2004510752A5 (enExample) | ||
| JP2019523295A5 (enExample) | ||
| RU2013155906A (ru) | Антитела анти-angptl3 и их применение | |
| IL295230A (en) | Combination therapy with anti-cd73 antibodies | |
| JP2023526774A5 (enExample) | ||
| RU2012156938A (ru) | Антитела против gdf8 человека | |
| JP2022169504A5 (enExample) | ||
| KR20110110349A (ko) | Ｉｌ-1 결합 단백질 | |
| JP2023524149A5 (enExample) | ||
| JP2022533538A5 (enExample) | ||
| JP2024001125A (ja) | Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 | |
| JP2024528877A5 (enExample) | ||
| JP2024534602A5 (enExample) | ||
| JP2024533119A5 (enExample) | ||
| JP2023502876A5 (enExample) | ||
| KR20110061630A (ko) | 질병 치료용 조성물 | |
| JP2025509567A5 (enExample) |